Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biopharmaceutical leader developing groundbreaking allogeneic CAR-T therapies through precision gene-editing technologies. This page provides investors and industry professionals with essential updates on the company’s clinical trials, regulatory milestones, and strategic developments.
Access real-time announcements including FDA submissions, partnership agreements, and research breakthroughs. Our curated collection features press releases on TALEN®-engineered therapies, hematopoietic stem cell advancements, and financial results – all critical for evaluating this innovator in off-the-shelf cancer treatments.
Key updates cover three focus areas: clinical trial phases for UCART candidates, intellectual property developments, and collaborative research initiatives. Bookmark this page to monitor progress in scalable cancer immunotherapies and maintain informed perspectives on Cellectis’ position within the competitive gene-editing landscape.
Cellectis announced its share and voting rights update as of October 31, 2021. The total number of shares in circulation is 45,475,310, while the total number of voting rights stands at 51,076,779. As a gene editing company, Cellectis focuses on CAR-T therapies for oncology and has 21 years of expertise in the field. Its approach includes off-the-shelf gene-edited CAR T-cells and a new platform targeting hemopoietic stem cells for various diseases. Cellectis is listed on Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
Cellectis S.A. reported a cash position of $216 million as of September 30, 2021, down from $274 million at year-end 2020. The company generated $11 million in revenues for Q3 2021, reflecting an increase from $9 million in Q3 2020, but a decrease to $53 million for the first nine months of 2021 compared to $67 million in the same period of 2020. R&D expenses rose to $34 million in Q3 2021, up from $20 million in Q3 2020. The net loss attributable to shareholders was $37 million for Q3 2021, compared to $30 million in Q3 2020. Preliminary clinical data will be presented at ASH 2021.
Cellectis, a gene-editing company, announced two abstracts accepted for presentation at the 63rd ASH Annual Meeting from December 11-14, 2021. They will share updated preliminary data from the BALLI-01 clinical trial involving UCART22 for relapsed/refractory B-cell acute lymphoblastic leukemia, and preclinical data on TALGlobin01 for sickle cell disease. The BALLI-01 trial data indicates good tolerance and CAR-T cell expansion. TALGlobin01 shows promise in correcting the mutated beta-globin gene, marking significant progress in gene therapy.
Cellectis S.A. (NASDAQ: CLLS) announced it will report its financial results for Q3 and the first nine months of 2021 after market close on November 4, 2021. A conference call is scheduled for November 5, 2021, at 8:00 AM EDT. The company focuses on gene editing technologies, particularly in developing CAR-T cell therapies for cancer and gene therapy programs for genetic disorders. Cellectis aims to provide life-saving treatments for various cancers and genetic diseases.
Cellectis (NASDAQ: CLLS) announced the upcoming presentation of pre-clinical data on its UCARTMESO product candidate at the Society for Immunotherapy of Cancer’s Annual Meeting, scheduled for November 10-14, 2021. UCARTMESO targets mesothelin-expressing solid tumors, leveraging TALEN® gene editing technology to enhance anti-tumor activity. The poster presentation will occur on November 12, focusing on engineered CAR-T cells designed to overcome tumor immunosuppression. Cellectis aims to advance its CAR-T immunotherapy programs and explore new therapeutic avenues.
Cellectis, a clinical-stage biopharmaceutical firm specializing in gene editing, reported its total shares and voting rights as of September 30, 2021. The company has 45,465,310 shares and 51,066,417 voting rights. Cellectis focuses on developing CAR-T immunotherapies and innovative therapeutic products aimed at treating various cancers, including AML and B-ALL, through its unique TALEN® technology. The company is committed to addressing unmet medical needs in oncology and hematological disorders.
On September 10, 2021, Cellectis reported its share and voting rights data as of August 31, 2021. The company had a total of 45,465,310 shares in capital and 51,067,217 voting rights. Cellectis is a gene editing company specializing in CAR-T immunotherapies, focusing on off-the-shelf gene-edited T-cells for cancer treatment. With over 21 years of expertise, it uses its TALEN® technology and PulseAgile system for therapeutic advancements. Cellectis aims to address blood disorders and cancers, enhancing its product pipeline.
Cellectis S.A. (NASDAQ: CLLS) announced its participation in five upcoming virtual investor conferences taking place between September 7 and September 15, 2021. The conferences include the Annual Biotech Symposium by Goldman Sachs, Citi’s Biopharma Conference, Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, and Baird Global Healthcare Conference. The live webcasts will be accessible on the Company’s investor webpage. Cellectis focuses on gene editing and immunotherapies aimed at treating various cancers and monogenic diseases, utilizing TALEN technology and an allogeneic approach.
Cellectis S.A. (NASDAQ: CLLS) announced preliminary positive data for UCARTCS1, a potential therapy for relapsed or refractory multiple myeloma, during the ASGCT 24th annual meeting. The company has completed successful training runs at its GMP facilities and disclosed new preclinical programs targeting various cancers and genetic diseases. As of June 30, 2021, Cellectis holds $257 million in cash, providing a runway into early 2023. However, the company reported a net loss of $40 million in Q2 2021, compared to $32 million in Q2 2020, highlighting financial challenges amid development efforts.
